VITA Magazine » COMMUNITAS » Yalla Italia! » SUBSCRIBE TO OUR NEWSLETTER »

Article written

  • on 26.03.2014
  • at 11:00 AM
  • by Kevin Hind

HIV drug could treat cervical cancer, new study shows 0

A commonly used oral, combination HIV drug — lopinavir and ritonavir — could be taken as a vaginal capsule to kill the virus that leads to cervical cancer in women, according to a phase I clinical trial in Kenya.

The findings of the new study were released this month (5 March) at a press conference in Nairobi, Kenya.

According to researchers from the Kenyatta National Hospital (KNH) in Nairobi, Kenya and the UK-based University of Manchester, who undertook the study, the combination drug lopinavir and ritonavir offer hope to many women — especially from low-resource countries — who die of cervical cancer, a disease caused by human papillomavirus.

Globally, there were 528,000 new of cervical cancer globally in 2012, causing 266,000 deaths, 85 per cent of which occurred in developing countries, according to estimates of GLOBOCAN, a project that tracks new cases of all types of cancer and the resulting deaths in 184 countries.cases

The early stage clinical trial carried out by Innocent Maranga, a gynaecologist at KNH and the UK-based researchers found out that the drug wiped out pre-cancerous cells in 90 per cent of trial participants with minimal side effects.

Maranga tells SciDev.Net that the trial screened 820 women at the hospital and finally settled on 40 patients who had early stage cervical cancer.

He says the women who took part in the study, which is yet to be published in a journal, were given one capsule of a combination drug, which has 133.3 milligrams lopinavir and 33.3 milligrams ritonavir, daily for two weeks in 2012.

continue reading on SciDev Net

Souce: SciDev Net 

subscribe to comments RSS

There are no comments for this post

Please, feel free to post your own comment

* these are required fields

Project by VITA SOCIETÀ EDITORIALE S.P.A.
P.IVA 11273390150
ISCRIZIONE ROC N.3275
Direttore Responsabile afronline.org: Giuseppe Frangi
©2011-2015